GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vencanna Ventures Inc (XCNQ:VENI) » Definitions » EPS (Diluted)

Vencanna Ventures (XCNQ:VENI) EPS (Diluted) : C$-0.01 (TTM As of Jul. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Vencanna Ventures EPS (Diluted)?

Vencanna Ventures's Earnings per Share (Diluted) for the three months ended in Jul. 2024 was C$-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jul. 2024 was C$-0.01.

Vencanna Ventures's EPS (Basic) for the three months ended in Jul. 2024 was C$-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jul. 2024 was C$-0.01.

Vencanna Ventures's EPS without NRI for the three months ended in Jul. 2024 was C$-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Jul. 2024 was C$-0.01.

During the past 3 years, the average EPS without NRIGrowth Rate was 41.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Vencanna Ventures's highest 3-Year average EPS without NRI Growth Rate was 68.80% per year. The lowest was -171.40% per year. And the median was 37.50% per year.


Vencanna Ventures EPS (Diluted) Historical Data

The historical data trend for Vencanna Ventures's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vencanna Ventures EPS (Diluted) Chart

Vencanna Ventures Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.01 - - -

Vencanna Ventures Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.01

Competitive Comparison of Vencanna Ventures's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Vencanna Ventures's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vencanna Ventures's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vencanna Ventures's PE Ratio distribution charts can be found below:

* The bar in red indicates where Vencanna Ventures's PE Ratio falls into.



Vencanna Ventures EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Vencanna Ventures's Diluted EPS for the fiscal year that ended in Apr. 2024 is calculated as

Diluted EPS (A: Apr. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.339-0)/181.283
=-0.00

Vencanna Ventures's Diluted EPS for the quarter that ended in Jul. 2024 is calculated as

Diluted EPS (Q: Jul. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.079-0)/222.645
=-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vencanna Ventures  (XCNQ:VENI) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Vencanna Ventures EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Vencanna Ventures's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Vencanna Ventures Business Description

Traded in Other Exchanges
N/A
Address
622 5th Avenue S.W, Suite 200, Calgary, AB, CAN, T2P 0M6
Vencanna Ventures Inc aims to provide investors with a diversified, high-growth, cannabis investment strategy through strategic investments and acquisitions focused throughout the value chain (cultivation, processing, and distribution, including ancillary businesses.
Executives
Jonathan Robert Sharun Senior Officer
William Scott Mcgregor Director
David Gordon Mcgorman Senior Officer

Vencanna Ventures Headlines

No Headlines